2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2...2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2060年达到中和的“双碳”目标。ESG与全球生态息息相关,也是推动经济高质量发展的重要工具,可以为中国实现“双碳”做出贡献。目前患肿瘤等疾病的人数不断攀升,肿瘤药物的创新研发具有重大意义,但同时制药又是重污染来源,亟需完善ESG治理。百济神州在生物创新药行业有一定的代表意义,本文以百济神州为例,研究其ESG信息披露的实践与可改进部分,从而给生物创新药行业带来借鉴意义。On April 12, 2024, the three major stock exchanges in Shanghai, Shenzhen and North China officially issued the Guidelines for Sustainability Reporting of Listed Companies (hereinafter referred to as the “Guidelines”), which will be implemented from May 1, 2024. In this context, President Xi Jinping has proposed to strive to peak carbon dioxide emissions by 2030 and achieve neutrality by 2060. ESG is closely related to the global ecology and is also an important tool to promote high-quality economic development, which can contribute to China’s “dual carbon” efforts. At present, the number of people suffering from tumors and other diseases is rising, and the innovative research and development of oncology drugs is of great significance, but at the same time, pharmaceuticals are a source of heavy pollution, and ESG governance needs to be improved urgently. BeiGene has a certain representative significance in the bio-innovative drug industry, and this article takes BeiGene as an example to study the practice and improvement of its ESG information disclosure, so as to bring reference significance to the bio-innovative drug industry.展开更多
文摘2024年4月12日,沪深北三大交易所正式发布了《上市公司可持续发展报告指引》(以下简称《指引》),并自2024年5月1日起实施。绿色环保和降低碳排放一直是全球人士关注的问题,在此背景下,习主席提出了努力将二氧化碳排放在2030年达到峰值,2060年达到中和的“双碳”目标。ESG与全球生态息息相关,也是推动经济高质量发展的重要工具,可以为中国实现“双碳”做出贡献。目前患肿瘤等疾病的人数不断攀升,肿瘤药物的创新研发具有重大意义,但同时制药又是重污染来源,亟需完善ESG治理。百济神州在生物创新药行业有一定的代表意义,本文以百济神州为例,研究其ESG信息披露的实践与可改进部分,从而给生物创新药行业带来借鉴意义。On April 12, 2024, the three major stock exchanges in Shanghai, Shenzhen and North China officially issued the Guidelines for Sustainability Reporting of Listed Companies (hereinafter referred to as the “Guidelines”), which will be implemented from May 1, 2024. In this context, President Xi Jinping has proposed to strive to peak carbon dioxide emissions by 2030 and achieve neutrality by 2060. ESG is closely related to the global ecology and is also an important tool to promote high-quality economic development, which can contribute to China’s “dual carbon” efforts. At present, the number of people suffering from tumors and other diseases is rising, and the innovative research and development of oncology drugs is of great significance, but at the same time, pharmaceuticals are a source of heavy pollution, and ESG governance needs to be improved urgently. BeiGene has a certain representative significance in the bio-innovative drug industry, and this article takes BeiGene as an example to study the practice and improvement of its ESG information disclosure, so as to bring reference significance to the bio-innovative drug industry.
